Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 3/20 | 0.50 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9417053 | 0.98 | GABBR2 (0.48) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL9155514 | 0.85 | GABBR2 (0.50) | GABBR2GABBR1GABRR1FDPSLMNA | |
| SCHEMBL7645645 | 0.76 | LMNA (0.54) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL10586239 | 0.75 | GABBR2 (0.55) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL9416951 | 0.74 | GABBR2 (0.38) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL5140906 | 0.71 | GABBR2 (0.56) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL160868 | 0.71 | LPAR1 (0.68) | FDPSLPAR1LPAR3SMPD1 | |
| SCHEMBL6360302 | 0.70 | GABBR2 (0.54) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| SCHEMBL2353617 | 0.67 | GABBR2 (0.83) | GABBR2GABBR1GABRR1CYP1A2TSHR | |
| Sgs-742 SCHEMBL195133 | 0.67 | GABBR2 (1.00) | GABBR2GABBR1GABRR1CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | SAEGIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | claimed |
| US-5545631-A | GAMMA-AMINOBUTYRIC ACID ANTAGONIST; TREATS PETIT-MAL TYPE EPILEPSIES | CIBA-GEIGY CORPORATION (US) | 1996-08-13 | — | — | US | claimed |
| EP-0463560-B1 | New antiepileptic agents | CIBA GEIGY AG (CH) | 1995-10-25 | — | — | EP | claimed |
| EP-0463560-A1 | New antiepileptic agents | CIBA-GEIGY AG (CH) | 1992-01-02 | — | — | EP | claimed |
| US-20050222093-A1 | Methods for restoring cognitive function following systemic stress | PEARLMAN RODNEY | 2005-10-06 | — | — | US | disclosed |
| EP-1372620-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | Saegis Pharmaceuticals (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | SAEGIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | disclosed |
| WO-2002074293-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | SAEGIS PHARMACEUTICALS INC (US) | 2002-09-26 | — | — | WO | disclosed |
| US-5545631-A | GAMMA-AMINOBUTYRIC ACID ANTAGONIST; TREATS PETIT-MAL TYPE EPILEPSIES | CIBA-GEIGY CORPORATION (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0463560-B1 | New antiepileptic agents | CIBA GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| US-5407922-A | GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1995-04-18 | — | — | US | disclosed |
| US-5300679-A | Antagonists to 4-aminobutyric acid | CIBA-GEIGY CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
| US-5229379-A | Gamma-aminobutyric acid antagonists | CIBA-GEIGY CORPORATION (US) | 1993-07-20 | — | — | US | disclosed |
| US-5190933-A | Treatment of cognitive and memory disorders | CIBA-GEIGY CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| EP-0463560-A1 | New antiepileptic agents | CIBA-GEIGY AG (CH) | 1992-01-02 | — | — | EP | disclosed |
| US-5064819-A | Antidepressants, anxiolytic agents, GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1991-11-12 | — | — | US | disclosed |
| US-5051524-A | Treatment of a phosphinic acid with an anhydrous protic medium | CIBA-GEIGY CORPORATION (US) | 1991-09-24 | — | — | US | disclosed |
| US-5013863-A | Learning enhancement | CIBA-GEIGY CORPORATION (US) | 1991-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222093-A1 | Methods for restoring cognitive function following systemic stress | CRH, BDNF, CHAT | GABBR2 2093/4885GABBR1 1947/4885GABRR1 420/4885 |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | CRH, BDNF, CHAT | GABBR2 2093/4885GABBR1 1947/4885GABRR1 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.